AbCellera Biologics (ABCL) EPS (Basic): 2020-2023
Historic EPS (Basic) for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$0.17.
- AbCellera Biologics' EPS (Basic) fell 70.00% to -$0.17 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.52, marking a year-over-year decrease of 192.86%. This contributed to the annual value of -$0.55 for FY2024, which is 7.84% down from last year.
- Latest data reveals that AbCellera Biologics reported EPS (Basic) of -$0.17 as of Q4 2023, which was down 70.00% from -$0.10 recorded in Q3 2023.
- AbCellera Biologics' 5-year EPS (Basic) high stood at $0.59 for Q1 2022, and its period low was -$0.17 during Q4 2023.
- Its 3-year average for EPS (Basic) is $0.05, with a median of -$0.05 in 2021.
- Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 4,400.00% in 2021, then tumbled by 450.00% in 2023.
- Quarterly analysis of 4 years shows AbCellera Biologics' EPS (Basic) stood at $0.52 in 2020, then slumped by 57.69% to $0.22 in 2021, then crashed by 145.45% to -$0.10 in 2022, then slumped by 70.00% to -$0.17 in 2023.
- Its EPS (Basic) was -$0.17 in Q4 2023, compared to -$0.10 in Q3 2023 and -$0.11 in Q2 2023.